[go: up one dir, main page]

WO1996016981A3 - Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no - Google Patents

Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no Download PDF

Info

Publication number
WO1996016981A3
WO1996016981A3 PCT/JP1995/002428 JP9502428W WO9616981A3 WO 1996016981 A3 WO1996016981 A3 WO 1996016981A3 JP 9502428 W JP9502428 W JP 9502428W WO 9616981 A3 WO9616981 A3 WO 9616981A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
suitable substituent
peptide compounds
prevention
treatment
Prior art date
Application number
PCT/JP1995/002428
Other languages
English (en)
Other versions
WO1996016981A2 (fr
Inventor
Yoshikuni Itoh
Toshiro Iwamoto
Takumi Yatabe
Hitoshi Hamashima
Takayuki Inoue
Seiji Hashimoto
Teruo Oku
Original Assignee
Fujisawa Pharmaceutical Co
Yoshikuni Itoh
Toshiro Iwamoto
Takumi Yatabe
Hitoshi Hamashima
Takayuki Inoue
Seiji Hashimoto
Teruo Oku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9424408A external-priority patent/GB9424408D0/en
Priority claimed from GBGB9504891.4A external-priority patent/GB9504891D0/en
Priority claimed from GBGB9510042.6A external-priority patent/GB9510042D0/en
Application filed by Fujisawa Pharmaceutical Co, Yoshikuni Itoh, Toshiro Iwamoto, Takumi Yatabe, Hitoshi Hamashima, Takayuki Inoue, Seiji Hashimoto, Teruo Oku filed Critical Fujisawa Pharmaceutical Co
Priority to EP95938602A priority Critical patent/EP0796270A2/fr
Priority to JP8518581A priority patent/JPH11501289A/ja
Priority to AU39937/95A priority patent/AU3993795A/en
Priority to US08/849,076 priority patent/US5932737A/en
Publication of WO1996016981A2 publication Critical patent/WO1996016981A2/fr
Publication of WO1996016981A3 publication Critical patent/WO1996016981A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nouveaux composés peptidiques de la formule (I) dans laquelle W représente un groupe de la formule (a), [R1 représentant hydrogène, halogène, alkyle inférieur etc., Q représentant CH ou N, L représentant notamment un radical bivalent de formule (b) (dans laquelle Y représente CH ou N, Z représente NH, O ou S, et --- représente une liaison simple ou double), etc.], A1 représente alkylène inférieur, -NHCO-, (c), (V représentant O ou S) ou -SO¿2?-, T représente hydrogène, aryle comprenant éventuellement un ou plusieurs substituants appropriés, un groupe hétérocyclique, hydroxy etc., A?2¿ représente alkylène inférieur, R8 représente hydrogène ou alkyle inférieur, etc., R3 représente hydrogène, aryle comprenant éventuellement un ou plusieurs substituants appropriés, hydroxy, hydroxy protégé etc., A3 représente une liaison ou alkylène inférieur, R9 représente hydrogène ou alkyle inférieur etc., et R4 représente notamment carboxy, carboxy protégé, carbonyle hétérocyclique comprenant éventuellement un ou plusieurs substituants appropriés, ou un groupe de formule (d) (dans laquelle R5 représente hydrogène ou alkyle inférieur, et R6 représente hydrogène, aryle, aralkyle inférieur comprenant éventuellement un ou des substituants appropriés etc.). Ces composés, ainsi qu'un sel pharmaceutiquement acceptable de ces derniers, sont utilisables comme médicaments.
PCT/JP1995/002428 1994-12-02 1995-11-29 Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no WO1996016981A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP95938602A EP0796270A2 (fr) 1994-12-02 1995-11-29 Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no
JP8518581A JPH11501289A (ja) 1994-12-02 1995-11-29 Ｎｏ介在疾患の予防および／または治療のためのペプチド化合物
AU39937/95A AU3993795A (en) 1994-12-02 1995-11-29 Peptide compounds for prevention and/or treatment of no-mediated diseases
US08/849,076 US5932737A (en) 1994-12-02 1995-11-29 Peptide compounds for treatment of no-mediated diseases

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9424408.4 1994-12-02
GB9424408A GB9424408D0 (en) 1994-12-02 1994-12-02 New peptide compounds
GB9504891.4 1995-03-10
GBGB9504891.4A GB9504891D0 (en) 1995-03-10 1995-03-10 New peptide compounds
GB9510042.6 1995-05-18
GBGB9510042.6A GB9510042D0 (en) 1995-05-18 1995-05-18 New peptide compounds

Publications (2)

Publication Number Publication Date
WO1996016981A2 WO1996016981A2 (fr) 1996-06-06
WO1996016981A3 true WO1996016981A3 (fr) 1996-09-06

Family

ID=27267497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/002428 WO1996016981A2 (fr) 1994-12-02 1995-11-29 Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no

Country Status (7)

Country Link
US (1) US5932737A (fr)
EP (1) EP0796270A2 (fr)
JP (1) JPH11501289A (fr)
AU (1) AU3993795A (fr)
IL (1) IL116211A0 (fr)
TR (1) TR199501527A2 (fr)
WO (1) WO1996016981A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951854B1 (en) 1996-12-23 2005-10-04 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US9585848B2 (en) 2012-12-07 2017-03-07 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914322A1 (fr) * 1996-05-27 1999-05-12 Fujisawa Pharmaceutical Co., Ltd. Nouveaux carboxamides d'indolyle et de benzofuranyle utilises comme inhibiteurs de la production d'oxyde nitrique
JP2001505585A (ja) * 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
AUPQ142599A0 (en) * 1999-07-05 1999-07-29 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
AUPQ386899A0 (en) 1999-11-04 1999-11-25 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
JP4603646B2 (ja) * 1999-11-15 2010-12-22 富士フイルムファインケミカルズ株式会社 新規なジピリジル誘導体
US20040053323A1 (en) * 2000-03-10 2004-03-18 Yoshinori Ishii Method of screening inducible nitric oxide synthase activation inhibitor
CA2408408C (fr) * 2000-05-12 2013-07-09 Genzyme Corporation Modulateurs de marquage du tnf-alpha
JP2004516237A (ja) 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体活性調節剤としてのピペリジンアミド類
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
PL366425A1 (en) * 2001-01-02 2005-01-24 Fujisawa Pharmaceutical Co, Ltd. Peptide compounds
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US20040063735A1 (en) * 2002-06-05 2004-04-01 Chaturvedula Prasad V. Calcitonin gene related peptide receptor antagonists
US7220862B2 (en) * 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DK1562571T3 (da) * 2002-11-21 2011-12-05 Genzyme Corp Kombination af et diamidderivat og immunsuppressive midler til hæmning af transplantatafstødning
AU2003291134A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
US7314872B2 (en) * 2003-08-20 2008-01-01 Irm Llc Inhibitors of cathepsin S
CN101365700A (zh) 2005-11-15 2009-02-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氮杂吲唑
WO2009105774A2 (fr) * 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Inhibiteurs aminoacides du cytochrome p450
WO2014134306A1 (fr) * 2013-03-01 2014-09-04 Zalicus Pharmaceuticals, Ltd. Inhibiteurs hétérocycliques du canal sodique
EP2970133B1 (fr) 2013-03-14 2018-10-24 Epizyme, Inc. Dérivés de pyrazole en tant qu'inhibiteurs de prmt1 et leurs utilisations
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム，インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153090A1 (fr) 2013-03-14 2014-09-25 Epizyme, Inc. Dérivés de pyrazole en tant qu'inhibiteurs de prmt1 et leurs utilisations
KR102028793B1 (ko) 2013-03-14 2019-10-07 에피자임, 인코포레이티드 아르기닌 메틸기 전이효소 억제제 및 이의 용도
WO2014153208A1 (fr) 2013-03-14 2014-09-25 Epizyme, Inc. Inhibiteurs d'arginine méthyltransférase et leurs utilisations
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
WO2014153100A2 (fr) 2013-03-14 2014-09-25 Epizyme, Inc. Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
WO2014153214A1 (fr) 2013-03-14 2014-09-25 Epizyme, Inc. Inhibteurs de l'arginine méthyltransférase et utilisations de ceux-ci
CN103626845B (zh) * 2013-09-30 2015-11-11 承德医学院 作为糖原磷酸化酶抑制剂的芳基并吡咯-2-甲酰胺二肽衍生物、其制备方法及医药用途
BR112022025037A2 (pt) 2020-06-10 2023-02-14 Aligos Therapeutics Inc Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394989A2 (fr) * 1989-04-28 1990-10-31 Fujisawa Pharmaceutical Co., Ltd. Composés peptidiques, leur préparation et médicaments les renfermant
EP0446699A1 (fr) * 1990-02-26 1991-09-18 Merrell Pharmaceuticals Inc. Inhibiteurs de la biosynthèse de l'oxyde nitrique
WO1992022569A1 (fr) * 1991-06-19 1992-12-23 Fujisawa Pharmaceutical Co., Ltd. Peptides antagonistes de la tachykonine
EP0525420A1 (fr) * 1991-07-01 1993-02-03 Mitsubishi Chemical Corporation Pseudopeptides et peptides caractérisés par une partie méthyle cétone substituée à la terminaison C comme inhibiteurs de thiol protéase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394989A2 (fr) * 1989-04-28 1990-10-31 Fujisawa Pharmaceutical Co., Ltd. Composés peptidiques, leur préparation et médicaments les renfermant
EP0446699A1 (fr) * 1990-02-26 1991-09-18 Merrell Pharmaceuticals Inc. Inhibiteurs de la biosynthèse de l'oxyde nitrique
WO1992022569A1 (fr) * 1991-06-19 1992-12-23 Fujisawa Pharmaceutical Co., Ltd. Peptides antagonistes de la tachykonine
EP0525420A1 (fr) * 1991-07-01 1993-02-03 Mitsubishi Chemical Corporation Pseudopeptides et peptides caractérisés par une partie méthyle cétone substituée à la terminaison C comme inhibiteurs de thiol protéase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D.HAGIWARA ET AL.: "Studies on Neurokinin Antagonists. 3. Design and Structure-Activity Relationships of New Branched Tripeptides Nalpha. (substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-(phenylmethyl)-L-phenylalaninamides as Substance P Antagonists", J.MED.CHEM., vol. 36, 1993, pages 2266 - 78, XP002006315 *
D.HAGIWARA ET AL.: "Studies on Neurokinin Antagonists. 4.", J.MED.CHEM., vol. 37, 24 June 1994 (1994-06-24), pages 2090 - 99, XP002006316 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951854B1 (en) 1996-12-23 2005-10-04 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US9585848B2 (en) 2012-12-07 2017-03-07 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
US9585847B2 (en) 2012-12-07 2017-03-07 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Also Published As

Publication number Publication date
US5932737A (en) 1999-08-03
IL116211A0 (en) 1996-01-31
TR199501527A2 (tr) 1996-07-21
EP0796270A2 (fr) 1997-09-24
JPH11501289A (ja) 1999-02-02
AU3993795A (en) 1996-06-19
WO1996016981A2 (fr) 1996-06-06

Similar Documents

Publication Publication Date Title
WO1996016981A3 (fr) Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no
GR3034542T3 (en) 4,5-diaryloxazole derivatives
AU3753695A (en) Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
CA2122236A1 (fr) Composes heterocycliques
AP9701041A0 (en) Pyridylpyrrole compounds.
NO891082D0 (no) Fremgangsmaate for fremstilling av peptidforbindelser.
GB9914486D0 (en) Medicaments
YU20999A (sh) Heterociklični derivati koji inhibiraju faktor xa
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
CA2293823A1 (fr) Derives de homo-erythromycine a -9-deoxo-9a-aza-9aa substitution en position 4
CA2336909A1 (fr) Derives de thiobenzimidazole utiles comme inhibituers de l'activite de la chymase humaine
AU6999796A (en) Heterocyclic compounds as bradykinin antagonists
ES8404990A1 (es) Un procedimiento para la preparacion de derivados de prolina.
GB9602029D0 (en) New heterocyclic compounds
NZ514558A (en) Viral treatment
NO974400L (no) Kombinasjonspreparater inneholdende benazepril eller benazeprilat og valsartan
NO905620L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
CA2282279A1 (fr) Atropisomeres de 3-heteroaryl-4(3h)-quinazolinones pour le traitement des troubles neurodegeneratifs et des troubles lies a un traumatisme du systeme nerveux central
CA2204204A1 (fr) Derives de glucides
CA2289017A1 (fr) Utilisation d'oxydes d'azote ou de promedicament a base de ces oxydes pour la prevention et le traitement therapeutique du cancer
CA2278057A1 (fr) Antagonistes de tachykinine
CA2207100A1 (fr) Derives pyrimidiniques
DE3162053D1 (en) N-acyl peptide compounds, processes for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN FI HU JP KR MX NO NZ RU UA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN FI HU JP KR MX NO NZ RU UA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 518581

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 08849076

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1995938602

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995938602

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995938602

Country of ref document: EP